A股異動 | 健民集團升近6% 七蕊胃舒膠囊今年正式上市銷售
格隆匯5月26日丨健民集團(600976.SH)升5.97%,報71.18元,總市值109億元。健民集團5月25日迴應投資者提問,公司產品七蕊胃舒膠囊今年正式上市銷售,正在做市場開發。此外,公司24日公佈,從國家藥品監督管理局網站獲悉,公司研發的鹽酸託莫西汀口服溶液獲批上市。鹽酸託莫西汀口服溶液是選擇性去甲腎上腺素再攝取抑制劑,適用於治療6歲及6歲以上兒童和青少年的注意缺陷/多動障礙(ADHD),是《中國注意缺陷多動障礙防治指南(第二版)》非中樞興奮劑類主要推薦藥物。口服溶液劑型較原膠囊劑型更適合兒童服用,提高用藥安全性及依從性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.